Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz (SWITCH-EE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00792584|
Recruitment Status : Completed
First Posted : November 18, 2008
Last Update Posted : September 12, 2011
Efavirenz causes neuropsychiatric side effects and sleep disturbance, including vivid dreams, dizziness, and abnormal tiredness. These symptoms are frequent during the first weeks of treatment, with subsequent attenuation but may not completely resolve even years after efavirenz initiation.
The investigators plan a twelve week, randomized, placebo-controlled, double-blind study. In group 1, efavirenz will be replaced with efavirenz placebo plus etravirine, in group 2, efavirenz would be continued, and etravirine placebo given in addition. After six weeks, patients in group 1 would switch to the regimen of group 2, and vice versa.
The primary endpoint of the trial will be patient preference. Sleep quality, daytime sleepiness, and anxiety will also be investigated.
|Condition or disease||Intervention/treatment||Phase|
|Sleep Disorders||Drug: etravirine Drug: efavirenz||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||June 2009|
patients treats with etravirine for 6 weeks
Patient receives etravirine/ placebo or efavirenz / placebo
patients treats with efavirenz for 6 weeks
patient receives efavirenz / placebo or etravirine / placebo
- Symptoms and neurological side effects of study drugs [ Time Frame: baseline, week 6 and week 12 ]
- Levels of daytime sleepiness [ Time Frame: baseline, week 6 and week 12 ]
- Sleep Quality [ Time Frame: baseline, week 6 and week 12 ]
- Patient preference [ Time Frame: 12 weeks ]
- Symptoms of depression, anxiety and stress will be assessed [ Time Frame: baseline, week 6 and week 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00792584
|Geneva, Switzerland, 1211|
|Principal Investigator:||Bernard BH Hirschel, Professor||Geneva Hospital|